Pharma Journalist

Gene Therapy Medical Affairs
2021-02-09 - 2021-02-11 | Digital Event
The inaugural Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role that Medical Affairs plays in delivering gene therapies to patients.
Industry pioneers from leading pharma and biotech companies at various stages of development and commercialization including Novartis Gene Therapy, Orchard Therapeutics & Bluebird Bio will share how to engage effectively with internal clinical and commercial teams as well as external HCPs, regulators and patient advocates to create a cohesive and streamlined launch strategy for complex, high priced gene therapy products and ultimately work to remove both barriers that exist for access to gene therapies.

Join this definitive, niche conference to delve into the unique Medical Affairs challenges encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch scrutiny, equipping you with the insights required to launch gene therapy products more efficiently and effectively than ever before.
This virtual event is set to be a highly interactive and engaging meeting. We fully understand (and quite frankly agree) that a presentation-heavy conference just isn’t up to scratch! As such we have created a new format for this meeting which maximises opportunities for engagement, discussion, and Q&A’s in order for you to get the best value from this meeting.
To know more about Gene Therapy Medical Affairs please click here.

RNA Therapeutics 2021
2021-02-10 - 2021-02-11 | Virtual Event
Innovations in technologies and applications of RNA-based medicine
RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.
The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

Join us in February 2021, as SMi’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications.
BENEFITS OF ATTENDING:

Explore in industry insights into how mRNA is being used to combat COVID-19
Engage in case studies exploring the growing therapeutic potential of RNA for rare diseases
Delve into future trends in AI application for optimal RNA therapeutics
Hear regulatory outlooks of the RNA landscape, clinical trials and looking ahead

View the full agenda and speaker line-up online: www.therapeutics-rna.com/pjwl
Focus day on RNA Interference – 12TH February 2021

As the industry of RNA therapeutics advances this year’s focus day will explore the growing potential of RNA interference. The focus day will present sessions that explore the evolving approaches to RNAi including: antifibrotic microRNA-based therapeutics for the treatment of Alport syndrome, self-deliverable RNAi and an exploration into how siRNA can be modified for self-delivery, and targeted delivery of nucleic acid therapeutics. Furthermore, this year’s focus day will be highlighting the emerging trends and future outlook of RNAi in the Pharmaceutical industry.
EARLY-BIRD RATES:

BOOK BY 30TH OCTOBER AND SAVE £400
BOOK BY 30TH NOVEMBER AND SAVE £200
BOOK BY 11TH DECEMBER AND SAVE £100

Registrations can be made on the event website at: www.therapeutics-rna.com/pjwl
Chairs for 2021:
Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech
Focus Day Chair for 2021: Shalini Andersson, Chief Scientist New Therapeutic Modalities & Head of Oligonucleotide Discovery, AstraZeneca
Featured speakers:

Dong Yu, Fellow, Senior Director, and Head, GSK Vaccines
Maria Luisa Pineda, CEO and Co-Founder, Envisagenics
Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA
Dong Ki Lee, CEO, OliX
Jennifer Pluim, Vice President Medical Affairs, ProQR
Arpan Desai, Team Leader, Advanced Drug Delivery, Pharmaceutical Sciences, AstraZeneca
Ruchi Shah, Senior Research Engineer, New Therapeutics Modalities, Eli Lilly and Company
Michael Mulqueen, Vice President Business Development, eTheRNA immunotherapies
Troels Koch, Founder & CEO, Aqiventa

Who should attend:

Research & Development Directors/Managers/Scientists
Heads of Clinical Development
Heads of Pre-Clinical Development
Head of RNA Biology
Head of RNA Formulation and Drug Delivery
Head of Pre-clinical R&D
Head of New Modalities
Head of Discovery
Senior Scientists
Chief Scientific Officers
Chief Medical Officers

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
Follow us: @SMiPharm #SMirna

SMi’s 5th Annual 3D Cell Culture Conference
2021-02-10 - 2021-02-11 | Online Access Only
Sponsored by: Celvivo
Chaired by: Stefan Przyborski, Professor of Cell Technology, Durham University
Developing Complex Physiologically Relevant Cell Models in Vitro
3D Cell Culture is gaining momentum in the pharmaceutical industry, with the global 3D Cell Culture market predicted to surpass a value of $3.2 Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery, predictivity and validation, safety, and toxicity.

SMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development, toxicity testing, and safety assurance. In addition, the conference will look into the newest breakthroughs in Organ Chip technology, 3D Multicellular scaffolding, Microphysiological Systems, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application.
Event Hashtag: #SMi3DCellCulture
HIGHLIGHTS FOR 2021

Discover the cutting-edge technology that is changing the face of pharmaceutical drug development
Explore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives
Insight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro
Discuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery
Assess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops

FEATURED SPEAKERS INCLUDE:

Suzanne Fitzpatrick, Senior Advisor for Toxicology, US Food and Drug Administration
Pelin Candarlioglu, Investigator – Bioengineer/Cell Biologist, GSK
Robert Vries, CEO, Hubrecht organoid Technology
Sakshi Garg, Lab Head, Discovery & Development Technologies, Merck Group
Rhiannon David, Scientific Lead Microphysiological Systems, AstraZeneca
Stephen J. fey, Founder and Chief Research Officer, CelVivo
Alejandro Amador, Director, Cellular Assays and Technologies, Incyte
Freddy Van Goethem, Scientific Director – Fellow, Predictive, Investigative, and Translational Toxicology, Johnson & Johnson; Janssen Pharmaceutical
Julian Bahr, Postdoctoral Fellow, Oncology, AstraZeneca
Pedro Pinto, Laboratory Manager, Urology, university of Greifswald – Medical Centre

View the full agenda: www.3D-cellculture.com/PJwl
WHO SHOULD ATTEND?
Biotech / Pharma Companies – Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO
Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer

5th Annual Liquid Biopsies for Precision Oncology Summit
2021-02-10 - 2021-02-12 | Digital Event
Welcome to the Digital 5th Liquid Biopsy for Precision Oncology Summit!
With two exciting LBx approvals in 2020 and investment pouring into the industry, these assays are primed to transform the cancer-care space. To realize these untapped opportunities, it is essential significant sensitivity, selectivity and analytical roadblocks are addressed to prove utility in the clinic.

The 5th Annual Liquid Biopsy for Precision Oncology Summit is a crucial date in the industry calendar, bringing together the entire value chain of oncology drug development to hear and collaborate around the latest advancements innovating cancer detection, diagnosis and monitoring.
This completely online meeting will allow you to discover how latest technologies are being applied to accurately detect and analyze circulating biomarkers earlier, effectively monitor treatment response and selectively stratify patient populations to enable delivery of targeted therapies in a time-efficient manner.
From biomarker validation through to reimbursement and regulatory, join your drug development peers striving to translate the clinical applications of liquid biopsies into a worldwide patient reality.
To know more about 5th Annual Liquid Biopsies for Precision Oncology Summit please click here.

CAR-TCR Summit Europe 2021
2021-02-16 - 2021-02-18 | Virtual Event
Accelerate the Bench to Bedside Development of Novel CAR Immunotherapies for Safe, Effective & Affordable Advanced Therapies

The CAR-TCR Digital Summit Europe is the definitive platform for the European community to advance novel cell constructs, breach the solid tumor microenvironment, and deliver affordable CAR and TCR technologies to patients in need.
Providing you with the most comprehensive program this side of the Atlantic, this summit brings you exclusive insights from the innovators breaking the glass ceiling in T cell engineering, manufacturing, safety management and patient accessibility.
To know more about CAR-TCR Summit Europe 2021 please click here.

Gene Therapy for Rare Disorders USA
2021-02-22 - 2021-02-25 | Virtual Event
The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.
With investment at an all-time high, and several indications in late-stage trials gearing up for approval, the meeting will leverage the experience from first to market pioneers, as well as unveiling the strategies drug developers are employing to improve efficacy, safety and commercial viability.

Incorporating insights from 90+ industry-leading speakers, this digital conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.
Join 500+ of your colleagues online to accelerate the progress of the next generation of gene therapies.
This is your comprehensive guide to define your commercial path forward.

Operationalize: Expanded Access Programs
2021-02-22 - 2021-02-24 | Virtual Event
Overcome the Operational Hurdles Preventing You From Bringing Treatments to Patients in Need: Say Goodbye to the Worry and Uncertainty of Setting Up and Managing an Expanded Access Program.

By bringing together the world’s leading thinkers in Expanded Access Programs, this exclusive platform will clarify the complex issues through end-to-end Expanded Access Program Operationalization. Through open discussion, sharing best-practice case studies, and removing hypotheticals: this event provides an unrivalled opportunity to solve your challenges across the entire program timeline.
Over the course of 3 interactive days, 20 expert speakers will share their insights on program set-up, US and EU regulatory pathways, product supply, data collection, using technology to streamline processes and patient communication, closing out programs and moving to commercialization. So, next February, join your peers from across the value chain to develop your own toolkit of solutions from the only case study led, operationally–focused access programs event.
To know more about Operationalize: Expanded Access Programs please click here.

Animal Health Innovation Europe
2021-02-22 - 2021-02-23 | Virtual
The 6th Annual Animal Health Innovation Europe taking place on the 22-23rd February 2021 will showcase the most exciting innovations in animal health and nutrition, connecting those businesses with financial investors and strategic corporate partners, making it the sector’s premier investment forum in Europe.

Join us to hear investment pitches, network with C-Suite Executives and learn from CEO-level panel discussions that address the trends and market dynamics of the animal health industry, across all species. This year’s virtual format gives us a unique opportunity with our programming to involve a wider array of stakeholders and key participants in the value chain so we can address the full scope of how animal health impacts pet owners, veterinarians, and farmers today. We have advanced our networking capabilities to help you recreate the unexpected business interactions that are so valuable at our face-to-face events, through virtual roundtable discussions, workshop groups and interactive content delivery.
Featuring speakers from industry leaders such as Elanco, Zoetis, Phibro, and many more, 2021 content will cover expanded insights on: sustainability and efficiency in the protein supply chain, the accelerated use of digital solutions in the pet sector, how the animal health industry will continue to generate value through the Covid-19 pandemic, and new approaches to stimulate technology adoption and enhance the productivity of European farmers.
Join us for the innovation showcase, a feature of the event that is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. Split between companion and production animal sectors, 20 start-ups, hand-picked by the Selection Committee (who all have an extensive breadth of experience and knowledge across animal health and nutrition industries), introduce themselves and their innovations and achievements on the main stage.
Book now to join us in shaping the future of animal health.

Purify'20
2021-02-23 | ITC Kohenur, Hyderabad, India
PURIFY – Chromatography Purification Conclave
PURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities, be it discovery, development or scaleups!
The pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification.

The attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches, niche topics, deeper understanding of preparative and process chromatography and allied fields, and upcoming application areas that will provide quality substance to the discerning scientists. So, if you wish to get that additional gram, which is purer, in as less a time, with minimal resources…there will surely be something for you at PURIFY conclaves!
The annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP, a Mumbai based company.
The PURIFY conclave is attended by analytical and research chemists, scientists with scale-up and process development knowledge, managers, group heads, natural product purification experts, experts from quality and manufacturing, academicians, policy makers, supply chain heads etc. of this pharmaceutical – APIs, peptides, proteins, oligonucleotides, chiral molecules, bio-pharmaceutical, fine chemicals, environmental studies, food and beverage, polymers, biotechnology, cosmetics and fragrance to understand the advancements in chromatography platforms.
The maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers, steered by our esteemed advisory board. (For more details please visit: https://www.linkedin.com/showcase/purifyconclave/) PURIFY’19 was attended by 113 delegates across 19 cities, spread across 51 corporates with 14 speakers and 6 display zones!
The knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related.
Looking forward to seeing you at PURIFY’20!
V: ITC Kohenur, Hyderabad
D: 23 February, 2021
To book your seats please call Rashi: +91-91366 00573

RAS – Targeted Drug Discovery – Digital Summit
2021-02-23 - 2021-02-25 | Digital Event, GMT
Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However, their specificity to only target G12C mutations, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike.

The Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C.
As part of our industry leading and dedicated RAS conference series, this exciting next iteration is shining the spotlight on:
§ Identifying key learnings from known pre-clinical and clinical data for viable KRAS direct inhibitors to effectively drug all RAS isoforms
§ Exploring G12C pre-clinical and clinical data to optimise future RAS targeting strategies
§ Learning from the patterns of RAS mutations to understand prognostic or predictive power in various cancer types beyond lung cancer
Join senior experts from leading biotech, large pharma and pioneering academic institutions at the Digital RAS- Targeted Drug Discovery Summit as they identify future models and strategies for streamlining anti-RAS therapeutics into the clinic.
To know more about RAS – Targeted Drug Discovery please click here.

9th Neurodegenerative Drug Development Summit
2021-02-23 - 2021-02-25 | Virtual Event
The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need.

Building on the success of last year’s meeting, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets, novel modalities and innovative trial design. Across 3 action-packed, case-study driven days and 2 parallel tracks of learning, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit.
Whether you are working in a team dedicated to Parkinson’s, Alzheimer’s, ALS, Frontotemporal Dementia or a rare neurodegenerative disorder, join this intimate, industry-led forum to not only to learn from those spearheading this space, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts.
To know more about 9th Neurodegenerative Drug Development Summit please click here.

Gene Therapy for Blood Disorders 2021
2021-03-09 - 2021-03-11 | Virtual Event
2020 has been an exciting year for Gene Therapies targeting Blood Disorders. Despite FDA’s recent rejection of BioMarin’s hemophilia gene therapy program, the clinical landscape is progressing quickly with Pfizer and Sangamo kicking off their phase 3 and bluebird bio receiving European approval for their beta-thalassemia candidate. With pipelines advancing and emerging companies joining the blood disorders field, it is essential for gene therapy developers to communicate and share lessons learned to accelerate their programs to market.

The 2nd Gene Therapy for Blood Disorders meeting is taking place in March 2021, focusing on the clinical and commercial challenges of developing gene therapies targeting hemophilia, sickle cell disease and beta thalassemia. Evaluate the best strategies for a commercial launch in blood disease and optimize your trial design to ultimately transform your clinical candidates into a commercial reality.
To know more about Gene Therapy for Blood Disorders please click here.

2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference
2021-03-11 - 2021-03-12 | Virtual
The Diagnostics sector has emerged as a prominent game changer in healthcare, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions, it needs to be quicker, précised, and accurate.
Point-of-care testing (POCT) is a growing testing. Today, you may see POCT in a hospital with handheld gadgets or small testers in emergency department, extensive care setting, popular clinical wards, and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient’s point of care.

In the era of improved diagnostics, our 2nd Annual Virtual Event on Infectious Disease Diagnostics and Point-Of-Care Testing will serve as a networking place for Diagnostics professional, Industrial specialists, and solution providers to address the rising innovation in its discipline and the way it can be used as disease prevention tool.
Event Website: https://bit.ly/3gNnkOq
Registration link: https://bit.ly/3oRX7kH

MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)
2021-03-11 | Virtual Event
High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event
The end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and biobetters, plasma therapy as well as others.
A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc can benefit from this unprecedented growth over the next 5 years.
This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space
Event Website: https://bit.ly/3qJYdQF
Registration link: https://bit.ly/2Mcpg8i

Targeting RNA Congress 2021
2021-03-15 - 2021-03-17 | Virtual Summit EST Timezone
Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins, therefore making it an obvious target. With Risdiplam being approved by the FDA in August, and several major collaborations also being penned throughout 2020, including a $190 million deal between Arrakis and Roche, it seems like a good time to target these protein precursors.

The Targeting RNA Congress will return for 2021, March 15-17, and will take a look at the latest techniques to analyse and predict protein structure, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent, rather than treat, disease.
Key Outcomes from the summit include:

Learn where to target your RNA molecules after exploring the newest biophysical techniques to analyse RNA structure, including NMR, Cryo-EM, and in silico modelling with Silvi Rouskin, (MIT), Wah Chiu (Stanford University) and Hashim Al Hashimi (Duke University).
Understand what makes a druggable RNA target and hear from expert RNA biologists to advise how best to drug your favourite RNA targets with Anima Biotech and Craig Blain (Arrakis).
Get translational insights into what considerations are important when creating a small molecule that targets RNA by learning how to develop tools for assessment of RNA targets with Amanda Garner (University of Michigan)
Hear what new techniques can help to drug these tricky targets, including RNAi, RNA degraders and RIBOTACs with Gene Yeo (UCSD), Jonathan Hall (Zurich) and Matt Disney (Scripps and Expansion).

To know more about Targeting RNA Congress please click here.

SMi’s 2nd Annual AI in Drug Discovery
2021-03-15 - 2021-03-16 | Online Access Only
Chaired by: Darren Green, Director of Molecular Design & Senior Fellow, GSK
Sponsored by: OpenEye Scientific Software
Exploring the latest Innovations in Machine Learning for Enhancing Discovery Pipelines
SMi is proud to present its 2nd Annual AI in Drug Discovery Conference, taking place on the 15-16 March 2021.
With the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3,900 million by 2027, the conference agenda will encompass key drivers leading the way into a shorter, cheaper, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’.

Furthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases, and will highlight key case studies across these themes, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail
Event Hashtag: #SMiAIDrugDis
HIGHLIGHTS FOR 2021 INCLUDE:

Discover the latest innovations in AI-based drug discovery platforms
Engage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines
Understand how AI can be effectively implemented to enhance productivity
Delve into best practices in data quality, curation, and validation
Explore how AI is being used to unlock therapies that have evaded traditional drug discovery

KEY SPEAKERS INCLUDE

Noor Shaker, CEO, Glamorous AI
Maria Luisa Pineda, Co-Founder & CEO, Envisagenics
Ed Addison, Co-founder, Chairman, and CEO, Cloud Pharmaceuticals
Liling Warren, Director, Head of Translational Medicine Statistics, Teva Pharmaceuticals
Lili Peng, Associate Director Scientific Ecosystem Analytics Lead, Biogen
Mark De Pristo, CEO, BigHat Biosciences
Philipe Moingeon, Head of Immuno-inflammation, Servier
Hugo Ceulemans, Scientific Director, Discovery Data Sciences, Janssen
Peter Henstock, Machine Learning & AI Lead, Pfizer
Naheed Kurji, CEO, Cyclica

WHO SHOULD ATTEND
CEOs, Presidents, Vice Presidents and Global Heads, Executive Directors, Vice President & Global head, Principal Scientists, Heads of Business Development, Directors of Pharma/Biotech firms.

Parallel Trade 2021 – Virtual conference: online access only
2021-03-22 - 2021-03-23 | Virtual Event
Exploring the challenges, practices and drivers in the aftermath of the transition for Parallel Trade
SMi present’s its 15th annual Parallel Trade virtual conference, taking place virtually on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end this year. As such, the UK will no longer be part of the EU free market. This will mean increased medicines prices, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment, exhaustion of rights will cease to apply to the UK, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution.
This conference will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states.
Register online for only £999: www.parallel-trade.com/pjwl
The benefits of attending:
Learn new perspectives and case studies through presentation, panel discussions and interactive workshops from industry KOLs. Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market. Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices. Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices. Discover what the industry has learnt from COVID-19 and the impact on export bans.
Plus, one post-conference interactive workshop
Workshop: The law of parallel trade: past, present and future
Workshop Leaders:
Christopher Stothers, Partner, Bruckhaus Freshfields Deringer
Sharon Malhi, Senior Associate, Antitrust, Competition and Trade, Bruckhaus Freshfields Deringer
Who should attend:
Vice President/ Heads of/General Managers:

International Trade and Relations
Supply Chain Development – Brexit
Brexit Implementation
Market Access
Supply Chain Manager
Parallel trade reporting
Regulatory Affairs
IP
Purchasing
Policy Patent Operations
European Affairs
Supply and Demand
Attorney
Distribution

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: @SMiPharm #SMi #SMiParallel

FcRn-Targeted Therapies for Autoimmune Disorders Summit
2021-03-23 - 2021-03-25 | Virtual Event
The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis, half-life extension, and recycling of human serum albumin and IgG, however in the case of more than 100+ rare and autoimmune disorders, this can not only be detrimental, but lethal to the health of the individual. Following the high profile J&J-Momenta deal, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020, other large players are poised to bring their candidates through the clinic in rapid succession.

The digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases.
The 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body.
Join 100+ experts online from companies such as CSL Behring, Eli Lilly, Roche, Momenta, Alexion, Argenx and more to discuss FcRn MOA, preclinical model selection and translation, high throughput assays for ligand screening, IgG engineering, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.

5th Annual MarketsandMarkets High Potent Medicines Virtual Conference (CET TIME ZONE)
2021-03-23 - 2021-03-24 | Virtual
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer. Globally, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases, glaucoma, and specifically cancer have a significant impact on the health status of people worldwide, with comparatively higher growth rates in developing countries.
The 5th Annual MarketsandMarkets High Potent Medicines Virtual Conference to be held on 23-24 March 2021. This conference would address the challenges in continual evolution of industry standards, technologies, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.
Event Website https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/
Registration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/register

Cytokine-Based Cancer Immunotherapies Summit
2021-03-24 - 2021-03-25 | Digital Event
Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment
The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.

Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapies approaches.
The virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients.
Join us and leading experts from Roche, CytomX, Philogen, Bristol-Myers Squibb, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose, determining the mechanisms of action and hear the latest data coming out of the clinic.
To know more about Cytokine-Based Cancer Immunotherapies Summit please click here.

Animal Microbiome Congress
2021-03-24 - 2021-03-25 | Virtual
The 4th Annual Animal Microbiome Congress taking place on the 24-25th March 2021 will provide the latest clinical data and facilitate interactions between academia and industry to accelerate the commercialization of animal microbiome research. This global market is forecast to grow to 9.7 billion by 2028 due to demand for innovation from the rapidly growing meat, aquaculture, and pet healthcare industries to meet an increasing need to replace antibiotics and satisfy the world’s growing hunger for protein. Over 4 years and 7 events, we have built an international animal microbiome community of 600+ people from 30+ countries.

Through comprehensive industry-academic discussion panels, engaging keynotes, interactive roundtables, and virtual networking this congress will enable participants to be at the forefront of modulating the animal microbiome to meet commercial goals, sustainably and safely. Our goal is to support smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market. Due to this year’s virtual format, we have advanced our networking capabilities to help you recreate the unexpected interactions that drive the future of your work. We have incorporated: network roulette enabling 30 + chance encounters, Deep Dive Roundtable groups of 9 people working together to tackle industry issues, interactive content delivery to facilitate discussion and pre-arranged meetings to broaden your network strategically.
Join us and discover the critical breakthroughs on: uncovering the full functional potential of the microbiome in aquaculture, production, and companion animals, improving health outcomes for production and companion animals, reducing the cost of animal ownership and making farming more sustainable, and translating academic research into commercial products whilst steering through challenging regulatory hurdles.
Book now to join us in unlocking the full functional potential of the Animal Microbiome.

8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)
2021-03-24 - 2021-03-26 | Virtual
The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 – 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data.
Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.
Event Website https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/
Registration link: https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register

5th Annual MarketsandMarkets Infection Control, Sterilization & Decontamination Virtual Conference (GMT)
2021-03-25 - 2021-03-26 | Virtual
Based on the survey on 1,000 hospitals in 33 countries, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection, surgical site infection and urinary tract infection.
The estimated number of patients in UK acquiring HAIs is approx. 300,000 a year, according to a report by National Institute for Health and Care Excellence (NICE). It costs the NHS approximately £1 billion a year, and £56 million of this is estimated to be incurred after patients are discharged from hospital. NHS has now adopted no-tolerance policy towards spread of HAIs.
MarketsandMarkets is organizing 5th Annual Infection Control, Sterilization and Decontamination in Healthcare Virtual Conference, scheduled for 25th & 26th March 2021, aiming at providing platform to experts from hospitals, academia, and government institutions discussing the innovations, challenges, and future aspects of infection control, decontamination, and sterilization.
Event Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/
Registration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/register

LEAP HR: Life Sciences Spring Edition
2021-03-29 - 2021-03-31 | Exclusive Virtual Conference
LEAP HR: Life Sciences Spring Edition is your best opportunity to uncover the radical strategies biopharma people leaders are putting in place to ensure they are a flexible employer of choice in a competitive industry.
This unique forum is shining a light on how the boldest life sciences HR leaders are rethinking the HR function and redefining the workforce of the future in order to continue to innovate and thrive in the face of change.
Step inside the HR innovation that is making a difference to employees, patients and customers – and leave with a brand new playbook for the people function to thrive in a post-vaccine world.
To know more about LEAP HR: Life Sciences Spring Edition please click here.

Gene Therapy Comparability
2021-03-30 - 2021-04-01 | Digital Event
The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development, supporting a seamless transition to the larger scales required for commercialization.
This meeting will unite large pharma and innovative biotechs including Pfizer, Biogen, BioMarin and Takeda as they share best practices, lessons learned and analytical data across the comparability lifecycle.

Focused specifically on enhancing your gene therapy comparability approach, join us to ensure you maintain safety, quality, consistency and efficacy throughout scale-up from clinical to commercial-scale manufacturing, and satisfy regulatory demands to avoid costly delays to clinical programs.
Incorporating insights from leading CMC, Regulatory, Analytical and Process Development experts, this is your opportunity to gain extensive technical information on challenges like ensuring manufacturing processes are comparable when changing facilities and cell lines, developing effective bioassays for use in comparability studies and handling the limited gene therapy lots available.
Join your peers online and discover:

How Biogen defined a robust comparability strategy for late phase gene therapy products
Gain insights into the planning and considerations for a comparability study and risk assessment and understand what defines process comparability vs analytical comparability with Amicus Therapeutics
Hear from the National Institute of Biology and discover if results of non-related analytical methods can be directly compared
Learn from the Italian Medical Agency and take a deep dive into regulatory expectations for ATMP comparability and comparability exercises
Explore next generation sequencing (NGS) and how its application can be utilized for comprehensive rAAV genome characterization with Biogen
Better understand the challenges associated with limited batch retention and sample availability in the context of comparability and learn best practices for mitigating such challenges with Gyroscope Therapeutics

View the full event guide to find out more!

Pharma: Clinical 2021
2021-04-07 - 2021-04-09 | Virtual Event
Reuters Events’ Clinical 2021 (April 7-9) is the new home of clinical collaboration, innovation and discovery. Join hundreds of pharma clinical innovators plus leaders from across the business, such as real-world evidence, medical, and patient centricity, alongside key regulatory bodies, providers, and patient representatives to form new collaborations and gain new insights through presentations, case-studies, workshops and collaborative working groups.
To know more about Pharma: Clinical 2021 please click here.

MarketsandMarkets qPCR and dPCR Virtual Conference
2021-04-15 - 2021-04-16 | Virtual Event
Advancing qPCR and dPCR technological developments and its applications in oncology and infectious disease diagnostics
As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use

MarketsandMarkets are proud to host its inaugural “qPCR and dPCR Virtual Conference” which will be held on 15th – 16th April 2021. The conference will focus on the latest developments in digital and real time PCR and also, its application in cancer diagnosis and infectious disease diagnostics
Event Website: https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/
Registration link: https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/

AI Driven Drug Repositioning and Repurposing Summit
2021-04-20 - 2021-04-21 | Virtual Event
The AI Driven Drug Repositioning & Repurposing Summit will bring together 80+ leaders in repurposing and pioneers in AI and machine learning to strategize how repurposing can reach its full potential to:

Improve time and cost savings of drug development
Leverage the safety advantage in reducing development risk
Unlock market potential advantage
Improve return on investment for repurposed drugs
Explore out-licensing options

This meeting aims to help pharma, biotech and academics stay ahead of the curve in their repurposing endeavors during a period exploding with new technologies. Join cutting-edge discussions with the like of AstraZeneca, BenevolentAI, and Healx, to solve ongoing technical challenges surrounding AI tools in repurposing, understand the delicate risk-reward balance in potential repurposing opportunities and explore lessons learned from AI applications in repurposing during Covid-19.
Featuring 2 days of jam-packed content, this digital summit will provide you with all the information you need to begin implementing AI tools into repurposing projects within your organization. What’s more, our digital platform allows you to take part in live Q&A with the presenters, take a tour of the virtual exhibition, and even join online rooms where you can join targeted interactive discussion groups!
To know more about AI Driven Drug Repositioning and Repurposing Summit please click here.

Anti-Infectives Drug Development – Digital Summit
2021-04-20 - 2021-04-22 | Digital Event, EDT
Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.

Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
What you can expect:

Reimagine anti-infective drug development to ensure economic sustainability, with insight from Merck, CARB-X & AlloVir

Explore the non-traditional approaches employed to combat multi-drug resistance, with insight from Locus Biosciences, Peptilogics & SciBac

Advance the clinical superiority of anti-infectives to drive commercial success, with insight from ContraFect & Summit Therapeutics

Target the unmet medical need to ensure drug development pipeline success, with insight from BioVersys, Entasis Therapeutics & Spero Therapeutics

Discover superior novel strategies to combat anti-microbial resistance, with insight from Techulon, MicuRX & Princeton University

To know more about Anti-Infectives Drug Development please click here.

4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - EST)
2021-04-22 - 2021-04-23 | Virtual Event
MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April, 2021.
While the 3rd annual virtual conference had discussions on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19.
Our aim for the 4th Annual Virtual Conference is to unite all stakeholders in a virtual room to learn how to overcome the challenges caused due to the pandemic, efficiently and effectively generating RWE for stakeholders including payers, patients and physicians.
Event Website https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/
Registration link: https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/register
